Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Carla Torre, José Guerreiro, Patrícia Longo, João Filipe Raposo, Hubert Leufkens & Ana Paula Martins. (2018) Effect of different methods for estimating persistence and adherence to new glucose-lowering drugs: results of an observational, inception cohort study in Portugal. Patient Preference and Adherence 12, pages 1471-1482.
Read now
Read now
Lawrence Blonde, Charmi Patel, Brahim Bookhart, Michael Pfeifer, Yen-Wen Chen & Bingcao Wu. (2018) A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin. Current Medical Research and Opinion 34:6, pages 1143-1152.
Read now
Read now
Articles from other publishers (18)
Wajd Alkabbani, Baiju R. Shah, Arsène Zongo, Dean T. Eurich, Mhd Wasem Alsabbagh & John‐Michael Gamble. (2023) Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom. Diabetes, Obesity and Metabolism 25:12, pages 3490-3500.
Crossref
Crossref
Lanting YangNico GabrielJiang BianLori A. BilelloDavene R. WrightInmaculada HernandezJingchuan Guo. (2023) Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis. Journal of Managed Care & Specialty Pharmacy 29:11, pages 1242-1251.
Crossref
Crossref
Michel Burnier. (2023) The role of adherence in patients with chronic diseases. European Journal of Internal Medicine.
Crossref
Crossref
David Seung U. Lee & Howard Lee. (2023) Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide. Journal of Diabetes Research 2023, pages 1-12.
Crossref
Crossref
Eugenia Piragine, Davide Petri, Alma Martelli, Vincenzo Calderone & Ersilia Lucenteforte. (2023) Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis. Journal of Clinical Medicine 12:5, pages 1981.
Crossref
Crossref
David Seung U. Lee & Howard Lee. (2022) Adherence and persistence rates of major antidiabetic medications: a review. Diabetology & Metabolic Syndrome 14:1.
Crossref
Crossref
Naoki Hirose, Naoto Tsujimoto, Taeko Katayose & Rina Chin. (2021) Utilization of glucagon‐like peptide‐1 receptor agonists and changes in clinical characteristics in patients with type 2 diabetes by chronic kidney disease stage in Japan: A descriptive observational study using a nationwide electronic medical records database. Diabetes, Obesity and Metabolism 24:3, pages 486-498.
Crossref
Crossref
M. V. Shestakova, A. S. Ametov, M. B. Antsiferov, T. P. Bardymova, F. V. Valeeva, G. R. Galstyan, T. Yu. Demidova, I. A. Karpova, T. P. Kiseleva, A. Yu. Mayorov, A. M. Mkrtumyan, S. V. Nedogoda, N. А. Petunina, L. A. Ruyatkina, L. A. Suplotova, O. Yu. Sukhareva, V. V. Fadeev & M. S. Shamkhalova. (2022) Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board. Diabetes mellitus 24:5, pages 479-486.
Crossref
Crossref
Federico Rea, Stefano Ciardullo, Laura Savaré, Gianluca Perseghin & Giovanni Corrao. (2021) Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting. Diabetes Research and Clinical Practice 180, pages 109035.
Crossref
Crossref
Yasushi Ishigaki, Alena Strizek, Toshihiko Aranishi, Nobuhiro Arai, Takeshi Imaoka, Zhihong Cai & Hiroshi Maegawa. (2020) Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57). Diabetes Therapy 12:1, pages 345-361.
Crossref
Crossref
Lawrence Blonde, Charmi Patel, Bingcao Wu, Yen-Wen Chen, Christopher D. Pericone & Brahim Bookhart. (2020) Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States. Advances in Therapy 38:1, pages 594-606.
Crossref
Crossref
Richard Ofori‐Asenso, Berhe W. Sahle, Ken Lee Chin, Mohsen Mazidi, Zanfina Ademi, Marie Louise De Bruin & Danny Liew. (2020) Poor adherence and persistence to sodium glucose co‐transporter 2 inhibitors in real‐world settings: Evidence from a systematic review and meta‐analysis. Diabetes/Metabolism Research and Reviews 37:1.
Crossref
Crossref
Aida Moreno-Juste, Beatriz Poblador-Plou, Mercedes Aza-Pascual-Salcedo, Francisca González-Rubio, Sara Malo, Julián Librero López, Victoria Pico-Soler, Eva Giménez Labrador, Sara Mucherino, Valentina Orlando, Enrica Menditto, Alexandra Prados-Torres & Antonio Gimeno-Miguel. (2020) Initial Therapy, Regimen Change, and Persistence in a Spanish Cohort of Newly Treated Type 2 Diabetes Patients: A Retrospective, Observational Study Using Real-World Data. International Journal of Environmental Research and Public Health 17:10, pages 3742.
Crossref
Crossref
Richard Ofori-Asenso, Jenni Ilomaki, K.L. Chin, Mohsen Mazidi, Ella Zomer, J.S. Bell, Dianna J. Magliano & Danny Liew. (2019) Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study. Diabetes Research and Clinical Practice 158, pages 107909.
Crossref
Crossref
Mukul Singhal, Hiangkiat Tan, Craig I Coleman, Michelle Han, Chi Nguyen & Michael Ingham. (2019) Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA. BMJ Open Diabetes Research & Care 7:1, pages e000704.
Crossref
Crossref
Richard Ofori-Asenso, Danny Liew, Samanta Lalic, Mohsen Mazidi, Dianna J. Magliano, Zanfina Ademi, J. Simon Bell & Jenni Ilomaki. (2019) Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study. Advances in Therapy 36:11, pages 3265-3278.
Crossref
Crossref
Craig I Coleman, Shivani Pandya, Li Wang, Onur Baser, Jennifer Cai, Mike Ingham & Brahim Bookhart. (2019) Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients. Journal of Comparative Effectiveness Research 8:11, pages 889-905.
Crossref
Crossref
György Jermendy, Zoltán Kiss, György Rokszin, Zsolt Abonyi-Tóth, István Wittmann & Péter Kempler. (2018) Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study. Diabetes Therapy 9:5, pages 2133-2141.
Crossref
Crossref